SLC5A2 and chronic kidney disease: In patients with type 2 diabetes and chronic kidney disease (CKD) or known ASCVD, the use of a Sodium-glucose co-transporter 2 (SGLT2) inhibitor is recommended, and their role is expanding beyond traditional indications, with emerging evidence also supporting a potential benefit in the cardio-oncology setting [67,68].